Eisler Capital (UK)’s Biogen BIIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
$730K Buy
+3,766
New +$788K ﹤0.01% 509
2024
Q2
Sell
-5,520
Closed -$1.2M 496
2024
Q1
$1.19M Sell
5,520
-5,119
-48% -$1.2M 0.01% 493
2023
Q4
$2.75M Sell
10,639
-23,052
-68% -$5.66M 0.02% 389
2023
Q3
$8.66M Buy
33,691
+20,012
+146% +$5.35M 0.05% 229
2023
Q2
$3.9M Buy
+13,679
New +$4.07M 0.03% 243
2022
Q4
Sell
-1,175
Closed -$314K 149
2022
Q3
$314K Buy
+1,175
New +$250K 0.02% 126
2022
Q2
Sell
-10,348
Closed -$2.12M 411
2022
Q1
$2.18M Buy
+10,348
New +$2.25M 0.04% 275

Other funds holding BIIB

Eisler Capital (UK)'s BIIB Position: Q3 2024 in Review

Eisler Capital (UK) opened a new position in Biogen (BIIB) in Q3 2024: 3,766 shares worth $730K. The stake represents ﹤0.01% of the portfolio and ranks #509 among its holdings. This is a return to the name: Eisler Capital (UK) previously reported a position in BIIB as recently as Q1 2024.

Eisler Capital (UK) first reported a position in BIIB in Q1 2022 and has held it in 7 quarters since. The position peaked at $8.66M in Q3 2023. 916 funds tracked by Wall St. Rank hold BIIB as of Q3 2024.

  • Eisler Capital (UK) held 3,766 shares of Biogen worth $730K as of Q3 2024.
  • Biogen was a new Eisler Capital (UK) position in Q3 2024.
  • Biogen made up ﹤0.01% of Eisler Capital (UK)'s portfolio in Q3 2024, its #509 holding.
  • Eisler Capital (UK) first reported a position in Biogen in Q1 2022 and has held it in 7 quarters since.
  • Eisler Capital (UK)'s Biogen position peaked at $8.66M in Q3 2023.
  • 916 funds tracked by Wall St. Rank held Biogen as of Q3 2024.

Based on Eisler Capital (UK)'s 13F filing for Q3 2024, filed 14 Nov 2024.